ID   Mero-82
AC   CVCL_2594
SY   MERO82
DR   cancercelllines; CVCL_2594
DR   Cell_Model_Passport; SIDM01894
DR   DepMap; ACH-001559
DR   ECACC; 09100105
DR   Wikidata; Q54905212
RX   PubMed=2474517;
RX   PubMed=25902174;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: ~24 hours (PubMed=2474517).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Arg (c.581T>G); ClinVar=VCV000376633; Zygosity=Unspecified (DepMap=ACH-001559).
CC   Omics: Deep exome analysis.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): DepMap=ACH-001559; ECACC=09100105
ST   Amelogenin: X
ST   CSF1PO: 10,13
ST   D13S317: 12
ST   D16S539: 12
ST   D18S51: 13
ST   D21S11: 30
ST   D3S1358: 18
ST   D5S818: 11,12
ST   D7S820: 10
ST   D8S1179: 13
ST   FGA: 24
ST   Penta D: 13
ST   Penta E: 11
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 16
DI   NCIt; C45662; Pleural epithelioid mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 21
//
RX   PubMed=2474517; DOI=10.1002/ijc.2910440212;
RA   Versnel M.A., Bouts M.J., Hoogsteden H.C., van der Kwast T.H.,
RA   Delahaye M., Hagemeijer A.;
RT   "Establishment of human malignant mesothelioma cell lines.";
RL   Int. J. Cancer 44:256-260(1989).
//
RX   PubMed=25902174; DOI=10.1097/JTO.0000000000000493;
RA   Miyanaga A., Masuda M., Tsuta K., Kawasaki K., Nakamura Y., Sakuma T.,
RA   Asamura H., Gemma A., Yamada T.;
RT   "Hippo pathway gene mutations in malignant mesothelioma: revealed by
RT   RNA and targeted exon sequencing.";
RL   J. Thorac. Oncol. 10:844-851(2015).
//